2023
Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology
Sarri G, Liu W, Zabotka L, Freitag A, Claire R, Wangge G, Elvidge J, Dawoud D, Bennett D, Wen X, Li X, Rentsch C, Uddin J, Ali M, Gokhale M, Déruaz‐Luyet A, Moga D, Guo J, Zullo A, Patorno E, Lin K. Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology. Clinical Pharmacology & Therapeutics 2023, 114: 604-613. PMID: 37342987, DOI: 10.1002/cpt.2977.Peer-Reviewed Original ResearchMeSH KeywordsAdultChildCOVID-19FemaleHospitalizationHumansMalePharmacoepidemiologyPost-Acute COVID-19 SyndromePrognosisConceptsPrognostic factorsUmbrella reviewHigh riskIntensive care unit admissionShort-term adverse outcomesCOVID-19AMSTAR-2 toolSystematic literature reviewCare unit admissionRisk of hospitalizationKey prognostic factorsHigh-risk groupCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 outcomesDisease 2019 pandemicComparative effectiveness researchInternational SocietyCOVID-19 disparitiesUnit admissionLong COVIDMale sexAdverse outcomesOptimal careFemale sexHeart disease
2022
Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform
Bhaskaran K, Rentsch CT, Hickman G, Hulme WJ, Schultze A, Curtis HJ, Wing K, Warren-Gash C, Tomlinson L, Bates CJ, Mathur R, MacKenna B, Mahalingasivam V, Wong A, Walker AJ, Morton CE, Grint D, Mehrkar A, Eggo RM, Inglesby P, Douglas IJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Parry J, Hester F, Harper S, Evans SJ, Bacon S, Smeeth L, Goldacre B. Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. PLOS Medicine 2022, 19: e1003871. PMID: 35077449, PMCID: PMC8789178, DOI: 10.1371/journal.pmed.1003871.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsCOVID-19 hospitalisationGeneral population controlsCOVID-19 groupCOVID-19 survivorsHospital admissionHigh riskInfluenza hospitalisationsCause mortalityCohort studyInfluenza patientsPrimary careGeneral populationInitial infectionAcute coronavirus disease 2019Lower respiratory tract infectionsSevere COVID-19 outcomesLong-term adverse outcomesCOVID-19 hospital admissionsSpecific causesPopulation controlsCause-specific hospitalisationRespiratory tract infectionsCause-specific outcomesPotential risk factors
2021
Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support
Crothers K, DeFaccio R, Tate J, Alba PR, Goetz MB, Jones B, King JT, Marconi V, Ohl ME, Rentsch CT, Rodriguez-Barradas MC, Shahrir S, Justice AC, Akgün KM, Group F. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. European Respiratory Journal 2021, 60: 2102532. PMID: 34824060, PMCID: PMC8841623, DOI: 10.1183/13993003.02532-2021.Peer-Reviewed Original ResearchConceptsIntensive respiratory supportHospitalised COVID-19 patientsCOVID-19 patientsNasal cannulaEarly dexamethasoneRespiratory supportSevere acute respiratory syndrome coronavirus 2Low-flow nasal cannulaAcute respiratory syndrome coronavirus 2Coronavirus disease 2019 (COVID-19) patientsRespiratory syndrome coronavirus 2Cox proportional hazards modelUS Veterans Affairs hospitalsSyndrome coronavirus 2Veterans Affairs hospitalProportional hazards modelCOVID-19Prior corticosteroidsCause mortalityMortality benefitTotal patientsCoronavirus 2Unexposed groupReal-world findingsEarly initiationPolypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study
Justice AC, Gordon KS, Romero J, Edelman EJ, Garcia BJ, Jones P, Khoo S, Re V, Rentsch CT, Tate JP, Tseng A, Womack J, Jacobson D. Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study. The Lancet Healthy Longevity 2021, 2: e639-e650. PMID: 34870254, PMCID: PMC8639138, DOI: 10.1016/s2666-7568(21)00206-3.Peer-Reviewed Original ResearchMeSH KeywordsAgingCohort StudiesFemaleFrailtyHIV InfectionsHIV SeropositivityHospitalizationHumansMalePolypharmacyConceptsVeterans Aging Cohort StudyMedication countDrug-drug interactionsAntiretroviral therapyObservational studyPhysiological frailtyVeterans Affairs Health Services ResearchMore drug-drug interactionsRisk of hospitalisationRisk of admissionAging Cohort StudyHIV-1 RNANon-ART medicationsAdverse health outcomesNational InstituteHealth services researchAdditional medicationObserved medicationActive medicationCause mortalityMore medicationsCohort studyPrescription fillsHIV statusPrescription medicationsSeverity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England
Grint DJ, Wing K, Houlihan C, Gibbs HP, Evans SJW, Williamson E, McDonald HI, Bhaskaran K, Evans D, Walker AJ, Hickman G, Nightingale E, Schultze A, Rentsch CT, Bates C, Cockburn J, Curtis HJ, Morton CE, Bacon S, Davy S, Wong AYS, Mehrkar A, Tomlinson L, Douglas IJ, Mathur R, MacKenna B, Ingelsby P, Croker R, Parry J, Hester F, Harper S, DeVito NJ, Hulme W, Tazare J, Smeeth L, Goldacre B, Eggo RM. Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England. Clinical Infectious Diseases 2021, 75: e1120-e1127. PMID: 34487522, PMCID: PMC8522415, DOI: 10.1093/cid/ciab754.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 alpha variantHospital admissionAlpha variantWild-type virusCox proportional hazards regressionS gene target failureIntensive care unitProportional hazards regressionSARS-CoV-2Pathways of diseaseHigher hazardWild-type casesCause deathCause mortalityCare unitHazards regressionIndividual-level demographicsPrimary careCommunity testingInfection incidenceNHS EnglandDeath dataHigh transmissibilityAdmissionSeverityRisks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform
Williamson EJ, McDonald HI, Bhaskaran K, Walker AJ, Bacon S, Davy S, Schultze A, Tomlinson L, Bates C, Ramsay M, Curtis HJ, Forbes H, Wing K, Minassian C, Tazare J, Morton CE, Nightingale E, Mehrkar A, Evans D, Inglesby P, MacKenna B, Cockburn J, Rentsch CT, Mathur R, Wong AYS, Eggo RM, Hulme W, Croker R, Parry J, Hester F, Harper S, Douglas IJ, Evans SJW, Smeeth L, Goldacre B, Kuper H. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. The BMJ 2021, 374: n1592. PMID: 34261639, PMCID: PMC8278652, DOI: 10.1136/bmj.n1592.Peer-Reviewed Original ResearchConceptsCovid-19 related hospital admissionRelated hospital admissionsNon-COVID deathsHospital admissionOpenSAFELY platformDown syndromeCohort studyHazard ratioCerebral palsyDisability registersGeneral practiceCOVID-19COVID-19 hospital admissionsMain exposure groupsCOVID-19 vaccinationHospital admission dataPatient-level dataLow event ratesNon-COVID causesCOVID-19 testingTargeted preventive measuresWave 2Wave 1Electronic health recordsProfound learning disabilitiesPharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans
Gerlovin H, Posner DC, Ho YL, Rentsch CT, Tate JP, King JT, Kurgansky KE, Danciu I, Costa L, Linares FA, Goethert ID, Jacobson DA, Freiberg MS, Begoli E, Muralidhar S, Ramoni RB, Tourassi G, Gaziano JM, Justice AC, Gagnon DR, Cho K. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. American Journal Of Epidemiology 2021, 190: 2405-2419. PMID: 34165150, PMCID: PMC8384407, DOI: 10.1093/aje/kwab183.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Bacterial AgentsAzithromycinCOVID-19COVID-19 Drug TreatmentDrug Therapy, CombinationFemaleHospitalizationHumansHydroxychloroquineIntention to Treat AnalysisMachine LearningMaleMiddle AgedPharmacoepidemiologyRetrospective StudiesSARS-CoV-2Treatment OutcomeUnited StatesVeteransConceptsUS veteransCOVID-19Veterans Affairs Health Care SystemRecent randomized clinical trialsAdministration of hydroxychloroquineEffectiveness of hydroxychloroquineRisk of intubationEffect of hydroxychloroquineElectronic health record dataRandomized clinical trialsTreatment of patientsUS veteran populationCOVID-19 outcomesCoronavirus disease 2019Health record dataRigorous study designsHealth care systemSurvival benefitTreat analysisEarly therapyHospitalized populationClinical trialsObservational studyDisease 2019HydroxychloroquineEthnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform
Mathur R, Rentsch C, Morton C, Hulme W, Schultze A, MacKenna B, Eggo R, Bhaskaran K, Wong A, Williamson E, Forbes H, Wing K, McDonald H, Bates C, Bacon S, Walker A, Evans D, Inglesby P, Mehrkar A, Curtis H, DeVito N, Croker R, Drysdale H, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Tomlinson L, Evans S, Grieve R, Harrison D, Rowan K, Khunti K, Chaturvedi N, Smeeth L, Goldacre B, Collaborative O. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. The Lancet 2021, 397: 1711-1724. PMID: 33939953, PMCID: PMC8087292, DOI: 10.1016/s0140-6736(21)00634-6.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionIntensive care unit admissionCOVID-19-related hospitalisationCare unit admissionObservational cohort studyCOVID-19 outcomesOutcomes of interestSouth Asian groupsOpenSAFELY platformICU admissionUnit admissionCohort studyEthnicity groupsMixed ethnicity groupCOVID-19-related hospital admissionsCOVID-19-related ICU admissionEthnic differencesAdverse COVID-19 outcomesMinority ethnic populationsSARS-CoV-2 testingMultivariable Cox regressionRisk of hospitalisationWhite groupPrimary care recordsPrimary care dataAssociation between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England
Forbes H, Morton CE, Bacon S, McDonald HI, Minassian C, Brown JP, Rentsch CT, Mathur R, Schultze A, DeVito NJ, MacKenna B, Hulme WJ, Croker R, Walker AJ, Williamson EJ, Bates C, Mehrkar A, Curtis HJ, Evans D, Wing K, Inglesby P, Drysdale H, Wong AYS, Cockburn J, McManus R, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Evans SJW, Bhaskaran K, Eggo RM, Goldacre B, Tomlinson LA. Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England. The BMJ 2021, 372: n628. PMID: 33737413, PMCID: PMC7970340, DOI: 10.1136/bmj.n628.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionIntensive care admissionHospital admissionCare admissionCohort studyCOVID-19Covid-19 related hospital admissionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Wave 2Primary care dataRelated hospital admissionsSyndrome coronavirus 2Adults 65 yearsCohort of adultsCOVID-19 outcomesCoronavirus disease 2019COVID-19 mortalityRisk of infectionWave 1UK pandemicHazard ratioIntensive careAbsolute risk
2019
Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study
Rentsch CT, Edelman EJ, Justice AC, Marshall BDL, Xu K, Smith AH, Crystal S, Gaither JR, Gordon AJ, Smith RV, Kember RL, Polimanti R, Gelernter J, Fiellin DA, Tate JP, Kranzler HR, Becker WC. Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study. AIDS And Behavior 2019, 23: 3340-3349. PMID: 31317364, PMCID: PMC7344341, DOI: 10.1007/s10461-019-02608-3.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid receiptCohort studyLong-term opioid therapyVeterans Aging Cohort StudyLatent growth mixture modellingPrescription opioid receiptObservational cohort studyAging Cohort StudyOpioid therapyCause mortalityHepatitis COpioid prescriptionsFuture prevention researchOUD diagnosisGrowth mixture modellingUS veteransHigh prevalenceLow doseHigh incidenceUse disordersPrevention researchGenetic discoveriesReceiptHIV
2015
Alcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011
Rentsch C, Tate JP, Akgün KM, Crystal S, Wang KH, Ryan Greysen S, Wang EA, Bryant KJ, Fiellin DA, Justice AC, Rimland D. Alcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011. AIDS And Behavior 2015, 20: 555-564. PMID: 25711299, PMCID: PMC4550577, DOI: 10.1007/s10461-015-1025-y.Peer-Reviewed Original ResearchConceptsAlcohol-related diagnosesHospitalization ratesUnited States veteransUninfected patientsCause hospitalizationHIV infectionStates veteransUninfected individualsMultivariable Cox proportional hazards modelsCox proportional hazards modelOverall hospitalization rateProportional hazards modelCancer admissionsAntiretroviral therapyMultivariable adjustmentHIV serostatusComorbidity variablesHospitalization trendsRelative riskHigh riskHazards modelHIVHospitalizationDisease categoriesPatients